The proposed study is a Phase 1/2 multi-center study evaluating the safety and efficacy of
erythropoietin (EPO) in combination with hydroxyurea in the treatment of chronic anemia in
patients with sickle cell disease (SCD).
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
Julia Xu
Collaborators:
American Society of Hematology Carnegie Mellon University